hVIVO plc

hVIVO plc is a British clinical research organisation (CRO) specialising in human challenge trials — studies in which healthy volunteers are deliberately exposed to a virus or bacterium under controlled conditions so that researchers can measure infection, disease progression and the effect of a candidate drug or vaccine. The company is best known for its work on respiratory pathogens, including influenza, respiratory syncytial virus (RSV), rhinovirus and coronaviruses, and it operates purpose-built quarantine and clinical facilities in London where volunteers are housed and monitored during studies. Its business model combines a clinical-trial services arm — running challenge studies and associated laboratory work for pharmaceutical and biotechnology clients — with a viral-sciences capability that supplies challenge agents and assays. Clients include large pharmaceutical companies, vaccine developers and academic groups seeking early, statistically efficient read-outs on whether a product works before committing to large and expensive field trials. hVIVO is a public limited company listed on London's AIM market, where it trades under the ticker HVO. It was created through the combination of Retroscreen Virology — a pioneer of the modern human challenge model founded by virologist John Oxford — with the clinical-trial services business of the Venn Life Sciences group, and it has since grown through acquisitions and facility expansion. The company is headquartered in London and sells its services internationally, principally into the UK, continental Europe and the United States. Positioned as a specialist rather than a broad CRO, hVIVO markets itself on speed, small study sizes and deep expertise in infectious disease. Its niche has gained visibility since the COVID-19 pandemic, which sharply raised interest in controlled human infection models as a way to test vaccines and antivirals quickly. The company's fortunes are tied to the flow of infectious-disease research funding and to the willingness of regulators and sponsors to use challenge studies in development programmes.

hVIVO's roots lie in Retroscreen Virology, a London-based company founded by the virologist John Oxford that pioneered the modern commercial human challenge model — paying healthy volunteers to be infected with a known virus in a controlled clinical setting so that the course of infection and the effect of experimental medicines could be observed directly. Retroscreen built a niche business running influenza and rhinovirus challenge studies for pharmaceutical sponsors and became one of the few organisations worldwide able to conduct such trials at scale. The company listed on London's AIM market as Retroscreen Virology Group and later rebranded as hVIVO, a name intended to evoke human volunteers and in-vivo science. A decisive step came with the acquisition of the clinical-trial services business of Venn Life Sciences, which combined hVIVO's challenge-study expertise with Venn's broader clinical operations and laboratory capabilities; the enlarged group took the hVIVO name. hVIVO subsequently invested in expanding its London facilities, including quarantine units where volunteers reside for the duration of a study, and broadened its challenge-agent portfolio beyond influenza and rhinovirus to include respiratory syncytial virus and, later, coronaviruses. The COVID-19 pandemic marked a turning point in the visibility of the sector: controlled human infection models were widely discussed as a route to faster vaccine and antiviral evaluation, and hVIVO positioned itself as a specialist partner for such work. The company has continued to grow organically and through smaller acquisitions, marketing itself as a specialist infectious-disease CRO rather than a full-service outsourcer. Its history is one of a small scientific pioneer evolving into a listed specialist services business whose fortunes track infectious-disease research priorities and the regulatory acceptance of challenge studies.

• Retroscreen Virology, the predecessor company, is founded in London by virologist John Oxford.

• The company lists on London's AIM market as Retroscreen Virology Group.

• Rebranding to hVIVO and combination with Venn Life Sciences' clinical-trial services business.

• Expansion of challenge-agent portfolio to RSV and coronaviruses alongside facility growth in London.

Specialist clinical research organisation focused on controlled human infection models for infectious disease and respiratory medicine.

• Influenza human challenge studies

• RSV human challenge studies

• Rhinovirus human challenge studies

• Coronavirus challenge models

• Quarantine clinical trial facilities

• 2026.08.27

  hVIVO acquires CRS Clinical Research Services Berlin[1]hVIVO收购CRS柏林临床研究服务公司investegate.co.uk

  hVIVO plc announced the acquisition of the entire issued share capital of CRS Clinical Research Services Berlin GmbH, a specialist Phase I/II clinical research unit focused on dermatology and women's health, for initial consideration of €0.025 million plus a three-year revenue-based earnout expected to total approximately €6 million in cash.

Read more

1. 1hVIVO收购CRS柏林临床研究服务公司investegate.co.uk
2. 2hVIVO plc: hVIVO acquires CRS Berlin, expanding expertise into dermatology and women's health marketsfinanznachrichten.de